




 Obstructive sleep apnea (OSA), a disorder affecting 2% to 7% of adults, 1-3 is characterized by recurrent 
collapse of the pharyngeal airway during sleep and 
 results in episodes of oxygen desaturation and arousal. 
Experimental data suggest that OSA predisposes 
 patients to increased rates of cardiovascular disease 
through such mechanisms as increased sympathetic acti-
vation, endothelial dysfunction, and oxidative stress. 4-6 
 Nevertheless, the epidemiologic evidence support-
ing a direct, causal link between OSA and cardiovas-
cular outcomes remains incomplete. OSA has been 
shown to be an independent risk factor for hyper-
tension in population-based cohort studies, 7,8 but 
prospective trials examining the effi cacy of contin-
uous positive airway pressure (CPAP) therapy on 
diurnal blood pressure provide somewhat confl icting 
results. 9-15 Overall, a metaanalysis of trials has demon-
strated a modest (2 mm Hg) improvement in diurnal 
systolic blood pressure associated with CPAP use. 16 
Two recent population-based studies have linked 
moderate-to-severe OSA 17 and severe OSA 18 with 
 increased risk of death, but these studies may have 
been confounded by the high rates of comorbid 
hypertension, obesity, and cardiovascular disease in 
 Background:  Evidence that continuous positive airway pressure (CPAP) reduces cardiovascular 
morbidity comes largely from observational studies. This association may be confounded if CPAP 
adherents are healthier in ways not measured by investigators. We assessed whether patients 
adhering to lipid-lowering medications were more adherent to CPAP. 
 Methods:  This was a retrospective cohort study undertaken at the Philadelphia Veterans Affairs 
(VA) Medical Center (2005-2006) of consecutive patients on lipid-lowering therapy newly initiat-
ing CPAP for obstructive sleep apnea. Adherence to medications dispensed via the VA closed- 
pharmacy system was measured as the proportion of days covered (   80% vs  , 80%) in the year 
prior to CPAP initiation. CPAP adherence was defi ned as   4 h/d of “mask-on” time, measured 
electronically daily during the fi rst week of CPAP. We examined the association between medication 
adherence and CPAP adherence using multivariable logistic regression. 
 Results:  Complete data were available for 117 of 142 (81.5%) subjects. After adjustment for age, 
race, medical comorbidity, and sleep apnea-related clinical factors, subjects with low medication 
adherence demonstrated a 40.1% (95% CI, 30.0-51.0) probability of using CPAP   4 h/d  compared 
with 55.2% (95% CI, 46.9-63.1) for subjects with adequate (   80%) medication adherence 
(adjusted for comparison, odds ratio (OR)  5 1.8 [95% CI, 1.0-3.3],  P  5 .04). Married patients were 
more adherent to medications and CPAP; inclusion of this factor reduced to nonsignifi cance the 
association of medication and CPAP adherence (OR  5 1.6 [95% CI, 0.9-2.8],  P  5 .12). 
 Conclusion:  Patients consistently refi lling lipid-lowering medications were more adherent to 
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and cardiovascular outcomes.  CHEST 2010; 137(1):102–108 
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[AHI]   5 events per hour) at the Philadelphia VA Medical Cen-
ter and newly initiated on CPAP therapy from January 1, 2005 to 
December 31, 2006. We included patients prescribed chronic 
lipid-lowering medications ordered via the VA pharmacy system 
at least 6 months prior to CPAP initiation and excluded subjects 
who had a history of prior CPAP use. The chronic lipid-lowering 
medications included 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors, or statins (simvastatin, atorvastatin, rosuvas-
tatin, fl uvastatin, lovastatin), and non-statin medications (gemfi brozil, 
colestipol, and ezetimibe). The Institutional Review Board at the 
Philadelphia VA Medical Center approved the study and waived 
informed consent because of the retrospective, observational study 
design. Ethical standards were used in the research. 
 Medication Adherence 
 Adherence to lipid-lowering medications was assessed by 
using the log of medication refi lls in the VA electronic pharmacy 
database to determine the total number of days that a candidate 
medication was supplied during the exposure window. 26,27 The 
exposure window was defi ned  a priori as a maximum of 365 
days and a minimum of 180 days before the initiation of CPAP 
therapy. The proportion of days covered (PDC) was calculated as 
the ratio of the total number of days that a candidate medication 
was supplied divided by the number of days in the exposure 
window. 26,27 Patients were designated as adherent on a given day 
during the exposure period if, at a minimum, the patient had at 
least one lipid-lowering medication of any dosage available on that 
day. Subjects were then classifi ed dichotomously as having ade-
quate vs low medication adherence based on a generally accepted 
threshold of 80% or more days covered during the exposure 
period. 28,29 
 Covariates 
 We collected data on individual demographic characteristics 
and medical comorbidities ( International Classification of 
Diseases, 9th ed [ICD-9] codes) and Charlson Index 30 from the VA 
electronic medical record. We reviewed sleep study interpreta-
tions and provider notes to confi rm the diagnosis of OSA, record 
BMI, the AHI on the diagnostic sleep study, the Epworth Sleep-
iness Scale 31 score before initiation of CPAP therapy, and the 
type of diagnostic sleep study used to confi rm the diagnosis 
of OSA (in-laboratory polysomnogram vs unattended, in-home 
study). 
 Sleep Studies 
 Patients were diagnosed with OSA at the Philadelphia VA 
according to a traditional in-laboratory, attended polysomnogram 
or an unattended, in-home sleep study. The in-laboratory poly-
somnogram was performed by an experienced technician in 
attendance using Sandman software (Sandman Diagnostic Sys-
tems; Nellcor-Puritan Bennett Inc.; Kanata, ON, Canada) as a 
full-night diagnostic polysomnogram generally followed by a full-
night CPAP titration polysomnogram or as a single split-night 
study. For in-home testing, patients were provided with a type 3 
portable monitor (Suzanne Portable Recording System; Nellcor 
Puritan Bennett; or Embletta; Embla; Broomfield, CO) that 
recorded nasal airfl ow, snoring, respiratory effort, body position, 
oxygen saturation, and heart rate. In-home diagnostic studies 
were generally followed by an unattended in-home automatic 
CPAP titration study (AutoSet Spirit; ResMed; Poway, CA) over 
4 to 5 days in the home. Both the in-laboratory and in-home 
diagnostic sleep studies were recorded and scored according to 
the policies and procedures of the American Academy of Sleep 
Medicine. 32,33 
subjects with more severe sleep apnea. 19 Long-term, 
randomized trials assessing the effi cacy of CPAP 
in reducing cardiovascular outcomes have not been 
conducted due to ethical concerns about randomiz-
ing OSA subjects to sham treatment. 20 
 Absent trial data for mortality, predominantly single-
center, observational studies report that patients with 
OSA who refuse or do not adhere to CPAP therapy 
experience higher rates of myocardial infarction, stroke, 
and death compared with CPAP adherents. 21-25 These 
nonrandomized, observational studies support the 
 notion that CPAP reduces cardiovascular risk in patients 
with OSA, but they fail to control for the possibility that 
CPAP-adherent patients may also be healthier than 
 patients who refuse or do not adhere to CPAP in ways 
not typically measured. For example, if CPAP adherence 
is associated with other health-promoting behaviors, then 
the magnitude of prior estimates of the impact of CPAP 
adherence on cardiovascular risk may be infl ated. 
 The purpose of our study was to test whether med-
ication adherence would be associated with CPAP 
adherence, independent of age, race, and clinical fac-
tors. We compared adherence to lipid-lowering med-
ications and adherence to CPAP in a Veterans Affairs 
(VA) cohort of patients with OSA newly initiated on 
CPAP therapy. 
 Methods 
 Design and Patient Population 
 We collected data on consecutive patients aged 18 years and 
older who were diagnosed with OSA (apnea-hypopnea index 
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median CPAP use  5 4.1 h/d (interquartile range 
[IQR], 0.1-6.4). Patients used CPAP for   4 h on 50.8% 
of nights (see Figs 3 and 4 in the online supplement). 
 Association of Medication and CPAP Adherence 
 Subjects with a history of adequate adherence to 
lipid-lowering therapy (PDC 80% or greater in the 
year before CPAP initiation) had substantially higher 
odds of adhering daily to CPAP therapy in unadjusted 
analysis (crude odds ratio [OR]  5 1.7, [95% CI, 
1.0-2.9],  P  5 .04) and in adjusted analysis (adjusted 
OR  5 1.8 [CI, 1.0-3.3],  P  5 .04) after accounting for 
the following potential demographic and clinical con-
founders: age, race, BMI, Epworth Sleepiness Scale, 
AHI, in-laboratory vs home unattended diagnostic 
sleep study, Charlson Index, and the fi rst day of CPAP 
use compared with subsequent days ( Table 3 ). 
 To provide a clinically meaningful estimate of the 
association of higher medication refi ll adherence 
(PDC   80%) and CPAP adherence based on the 
model presented in  Table 3 , we converted the odds 
ratios of initial daily CPAP use   4 h into estimated 
probabilities. After adjustment for all factors in  Table 3 , 
the probability of CPAP use   4 h  5 40.1% (CI, 30.0-
51.0) for subjects with a history of low adherence to 
lipid-lowering medications (PDC  , 80%) compared 
with 55.2% (95% CI, 46.9-63.1) for subjects with a 
history of high adherence to lipid-lowering therapy 
(PDC   80%) ( Fig 2 ). 
 To assess what other patient-specifi c factors might 
codetermine adherence to lipid-lowering medica-
tions and CPAP adherence, we examined marital 
 status. We found that married patients (n  5 56) had 
 CPAP Initiation 
 All subjects underwent an education program on OSA and use 
of CPAP therapy prior to initiating treatment, including face-
to-face information provided by the treating physicians as well as 
by the respiratory therapists and nurses. In addition, patients were 
shown a video and given written pamphlets specifi cally made to 
educate them about OSA and CPAP therapy. After the sleep test-
ing was completed, a board-certifi ed sleep specialist prescribed 
fi xed CPAP to each patient. All patients received a CPAP unit 
(RemStar Pro; Phillips; Murrayville, PA) that recorded daily mask-on 
time (ie, the time the CPAP circuit was pressurized at the pre-
scribed level) on a data card. The data card was collected approxi-
mately 1 week after delivery of the CPAP device. The fi rst day of 
CPAP use was defi ned as the initial day during which any pressur-
ized mask-on time was recorded by the CPAP electronic card 
monitor after delivery of the CPAP device to the patient. 
 Outcome and Statistical Analysis 
 Daily CPAP adherence during the fi rst 7 days of therapy was 
the primary outcome for our analyses, and was defi ned  a priori 
as   4 h/d of mask-on time. 34,35 The fi rst week of CPAP closely 
correlates with subsequent adherence. 34,36,37 Daily CPAP adherence 
was modeled as a dependent, dichotomous  repeated outcome 
variable using multivariable logistic regression STATA 9.0 (STATA 
Corporation; College Station, TX). We accounted for the within-
subject correlation of the repeated outcome of daily CPAP use 
using general estimating equations with an exchangeable correla-
tion matrix structure. 38 We included a within-patient factor indicating 
whether the night observed was the fi rst night vs the remaining 
nights, as CPAP adherence on the fi rst night was observed to be 
shorter than that on subsequent nights. 
 Results 
 Of 330 subjects who were diagnosed with OSA and 
newly initiated on CPAP therapy from 2005 to 2006, 
142 subjects met study criteria for exposure to lipid-
lowering therapy prior to OSA diagnosis. Complete 
clinical and CPAP data were available for analysis for 
117 (82%) of the 142 subjects ( Fig 1 ). The study 
cohort was 97% male and had a high level of OSA 
disease severity (mean AHI 40.2  6 25.5 events/h) and 
comorbid medical disease ( Table 1 ). There were no 
signifi cant differences in baseline demographic or 
clinical characteristics or medication adherence to 
lipid-lowering therapy among those excluded because 
of missing data (n  5 25) compared with those included 
in the study (n  5 117). 
 The PDC for lipid-lowering medications during 
the observation window in the year before CPAP ini-
tiation averaged 80.1% (SD, 22.4) ( Figs 1 and 2 in the 
online supplement). Nearly all subjects (114 of 117) 
were taking statin medications ( Table 2 ). Mean 
adherence was similar among subjects receiving  statin 
medications, non-statin lipid-lowering medications, 
or combinations of the two medication classes. 
 Across the 787 total patient-days observed during 
the fi rst week of CPAP therapy for the 117 subjects, 
 Figure 1. Philadelphia VA study cohort (2005-2006). CPAP  5 con-
tinuous positive airway pressure; VA  5 Veterans Affairs. 
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the median (   88%) also did not affect the associa-
tion of medication and CPAP adherence (adjusted 
OR  5 2.0 [CI, 1.1-3.4],  P  5 .02). Limiting our analyses 
to the subset of subjects with a full 7-day CPAP window 
of observation (n  5 103) resulted in a similar point 
estimate of the association of medication and CPAP 
adherence, albeit with a loss of power in this subset 
analysis (adjusted OR  5 1.8 [CI, 1.0-3.2],  P  5 .06). 
Varying the outcome defi nition of CPAP adherence 
over a 1-h range did not affect the results: CPAP ad-
herence   3.5 h (vs  , 3.5 h), adjusted OR  5 1.8 (CI, 
1.0-3.3),  P  5 .04; CPAP adherence   4.5 h (vs  , 4.5 h), 
adjusted OR  5 1.8 (CI, 1.0-3.2),  P  5 .04. 
 Discussion 
 In this retrospective cohort of 117 veterans newly 
initiated on CPAP therapy for OSA who had been 
exposed to lipid-lowering therapy, we found that 
patients who had higher rates of medication adher-
ence (PDC   80%) were signifi cantly more likely 
to adhere   4 h to CPAP therapy on a daily basis. 
Consistent with several prior studies, clinical factors 
of disease severity, daytime sleepiness, or medical 
comorbidity did not predict daily CPAP use. 39,40 
 These results suggest that a so-called “healthy-user” 
effect could be present in observational studies of CPAP 
use, such that subjects who adhere well to medica-
tions for chronic conditions, such as hyperlipidemia, 
are also more likely to adhere regularly to CPAP. If 
confi rmed in other studies, these results suggest that 
in nonrandomized studies, adherence to CPAP may 
be a marker for a collection of health-promoting 
higher medication adherence than nonmarried patients 
(n  5 61) (84.9% [SD, 19.3] vs 75.8% [SD, 24.3], 
 P  5 .03) and higher CPAP adherence across all 
patient days (4.6 h per day [SD, 3.1] vs 3.2 [SD, 3.1], 
 P  , .001). Inclusion of marital status in the fi nal 
model reduced the adjusted association of medica-
tion and CPAP adherence to a statistically nonsignifi -
cant  P value (OR  5 1.6 [CI, 0.9-2.8],  P  5 .12). 
 Sensitivity Analyses 
 In sensitivity analyses, adjusting for differences 
in number of days on lipid-lowering therapy prior 
to CPAP initiation did not affect the association of 
higher medication and CPAP adherence (adjusted 
OR  5 1.9 [CI, 1.1-3.4]  P  5 .03). Changing the threshold 
for medication adherence from the mean (   80%) to 
 Table 1— Baseline Patient Characteristics (n 5 117 ) 
Variable Value






Married, b % 47.9
Medical comorbidities c 
Charlson Index, median (IQR) 2 (1-4)
Hypertension, % 86.3
Diabetes mellitus, % 69.2
Coronary artery disease, % 49.6
Hyperlipidemia 91.5
Chronic obstructive lung disease, % 34.2
BMI, kg/m 2 , mean (SD) 35.1 (6.7)
Epworth Sleepiness Scale, mean (SD) 11.9 (5.5)
Apnea-hypopnea index, mean (SD) 40.2 (25.5)
Type of diagnostic sleep study, in-laboratory 
  (vs home, unattended), %
53.9
Total number of d in lipid-lowering drug exposure 
   window, y before CPAP initiation, 
median (range) d 
365 (208-365)
Total patient-d of CPAP observation, number 787
Number of CPAP patient-d observed per subject, e 
  median (range)
7 (1-7)
Median h of CPAP use per d, across all 
  patient-d, median (IQR)
4.1 (0.1-6.4)
CPAP  5 continuous positive airway pressure; ICD-9  5  International 
Classifi cation of Disease , 9th ed.; IQR  5 interquartile range.
 a Other race category consists of Pacifi c Islander, Asian, and Indian 
American (n  5 5), and race classifi cation missing (n  5 4).
 b Nonmarried patients: separated/divorced (26.5%), never married 
(19.7%), widowed (6.0%).
 c Medical comorbidities measured according to ICD-9 classifi cation. 
Of the 10 subjects on lipid-lowering therapy without an ICD-9 
diagnosis of hyperlipidemia, seven had comorbid diagnoses of diabetes 
mellitus and one had comorbid coronary artery disease.
 d Drug ascertainment exposure window is defi ned as a minimum 180 
and a maximum 365 d before CPAP initiation.
 e A full 7 patient-d on CPAP were observed for 103 (88.0%) of subjects; 
6 patient-d were observed for eight (6.8%); and   5 patient-d on 
CPAP for six (5.1%) of the 117 subjects.
 Table 2— Review of Pharmacy Refi ll Adherence to 





Adherence to lipid-lowering therapy 117 80.1 (22.4)
Prescribed simvastatin alone 81 79.2 (23.0)
Prescribed atorvastatin, rosuvastatin, 
  lovastatin, or fl uvastatin
18 79.3 (21.3)
Prescription switched among statin drugs 
   (simvastatin, atorvastatin, rosuvastatin, 
lovastatin, fl uvastatin)
5 78.8 (31.6)
Prescribed a statin and a non-statin a 
  lipid-lowering drug
10 89.3 (16.7)
Prescription of a non-statin a lipid-
  lowering medication exclusively
3 83.7 (12.4)
Pharmacy refi ll adherence is measured as the PDC or the percent of 
d with a lipid-lowering medication available divided by the total 
number of d on drug therapy during the total d on therapy in the 1-y 
exposure window before CPAP initiation. Analysis of variance for 
difference among groups,  P  5 .75. A statin is defi ned as a 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitor. PDC  5 proportion 
of days covered. See Table 1 for expansion of other abbreviation.
 a Colestipol, gemfi brozil, or ezetimibe.
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adherence. The difference in the study results of 
 Villar and colleagues and our own may be possibly 
explained by our more precise monitoring of initial 
daily CPAP therapy, differences in the population 
studied, or differences in the metric used to track 
medication adherence. 42 
 Notwithstanding the negative fi ndings of Villar and 
colleagues, 41 the impact of the healthy-user effect 
has been noted in numerous other clinical settings, 
including the association of hormone replacement 
therapy and improved cardiovascular outcomes (doc-
umented in observational studies but subsequently 
refuted by randomized, controlled trials); 43 the 
improved survival found in large-scale cardiovascular 
trials among placebo-adherent subjects compared with 
placebo-nonadherent subjects; 44-47 and the higher use 
of preventive health services, such as immunization, 
among elderly patients who adhere regularly to lipid-
lowering therapy vs medication nonadherent sub-
jects. 48 In these examples, adherence to treatment is 
a marker for other unmeasured behaviors or charac-
teristics that presumably help to explain the improved 
outcomes. 
 What might explain a healthy-user effect? It is cer-
tainly plausible that some patients are generally more 
adherent to medical advice or social norms than oth-
ers. There may also be differences in psychologic fac-
tors, such as active coping styles or higher perceived 
self-effi cacy, among adherers and nonadherents. 49,50 It 
is also possible that other factors might codetermine 
adherence to CPAP and lipid-lowering medications. 
In our sample, we found that married patients had 
higher medication adherence and higher CPAP 
adherence, and inclusion of this variable in the analysis 
attenuated the observed association between medi-
cation and CPAP to a nonsignifi cant  P value (OR  5 1.6 
[CI, 0.9-2.8],  P  5 .12). Indeed, it seems plausible 
that married patients have more internal and external 
cues that prompt adherence to medications and CPAP. 
As a future direction, health-promoting behaviors, 
such as medication adherence, primary care follow-up, 
or immunization records, as well as marital status or 
other important sociodemographic factors, might 
simultaneously be assessed in observational studies 
of CPAP use to obtain a less biased  estimate of the 
association of CPAP use and improved cardiovascular 
morbidity. 
 Limitations 
 Several important limitations should be considered. 
First, our study was performed in a predominantly male, 
veteran cohort, which might limit generalizability. 
Our study fi ndings should be assessed in other 
populations of patients with OSA. Second, although 
prescription-refi ll adherence has been well validated 
behaviors that together could reduce cardiovascular 
morbidity. Simply put, those who adhere to CPAP may 
also be taking their statins and other medications, 
and it may be adherence to statins, other types of 
medications, and other health-promoting behaviors 
that explain some of the observed reduction in cardio-
vascular disease associated with CPAP adherence. 
 To date, the only similar study in the literature 
exploring a healthy-user effect in CPAP adherence, 
to our knowledge, was conducted by Villar et al. 41 
In their investigation, Villar and colleagues studied 
medication-refi ll-patterns data among those subjects 
who accepted vs those who declined CPAP and found 
that CPAP adherence was unrelated to medication 
 Table 3— Adjusted Odds Ratios for Adequate Initial 
Adherence to CPAP (n  5 117) 
Variable
Adjusted OR 
(95% CI)  P Value
Lipid medication adherence   80% 
 (vs  , 80%) a 
1.8 (1.0-3.3) .04
Age (per 10-y increase) 1.3 (0.9-1.6) .13
Race, black (vs white/other) b 0.8 (0.5-1.5) .55
BMI (per SD change) 0.8 (0.6-1.0) .10
Epworth Sleepiness Score (per SD change) 1.1 (0.9-1.5) .41
Apnea-hypopnea index (per SD change) 1.0 (0.8-1.3) .91
Diagnostic sleep study, unattended 
 (vs in-laboratory)
1.2 (0.7-2.1) .44
First night of CPAP use (vs subsequent 
 nights)
0.4 (0.3-0.6)  , .001
OR  5 odds ratio. See Table 1 for expansion of other abbreviation.
 a Pharmacy refi ll adherence is measured as the percent of d covered 
with a lipid-lowering medication, calculated as the number of d 
covered divided by the total number of d on drug therapy during the 
exposure window in the year before CPAP initiation.
 b Other race category consists of Pacifi c Islander, Asian, and Indian 
American (n  5 5), and race classifi cation missing (n  5 4).
 Figure 2. Adjusted probability of initial CPAP use   4 h, by 
lipid-adherence subgroup (n  5 117). Medication adherence is 
measured as the PDC, calculated as the number of d with medica-
tion available from the Veterans Affairs pharmacy divided by the 
total number of d exposed in the year before CPAP therapy. Esti-
mates are adjusted for age, race, BMI, Epworth Sleepiness Scale, 
apnea-hypopnea index, in-laboratory vs unattended sleep study, 
Charlson Index, and CPAP use on fi rst night vs subsequent 
nights. PDC  5 proportion of days covered. See Figure 1 for  expansion 
of other abbreviation. 
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as a method for measuring medication adherence 
and is associated with important clinical outcomes, 
such as glycosylated hemoglobin, low-density lipid 
levels, diastolic blood pressure, hospitalization, and 
mortality, 27 this method of measuring medication 
adherence does not directly assess actual daily pill-
taking and might therefore result in some degree 
of exposure misclassifi cation. Prospective assessment 
via electronic pill cap monitoring might allow a more 
direct, daily comparison of medication and CPAP 
adherence. A third potential limitation is outcome 
misclassifi cation arising from our having measured 
CPAP adherence daily over the fi rst week of use and 
not for longer periods of time. We are reassured, 
given that numerous studies have demonstrated that 
CPAP adherence during the first week interval 
closely predicts subsequent adherence. 26,36,37 Last, 
given that our study is observational, additional 
unmeasured or unobserved confounders could explain 
the observed association of medication and CPAP 
nonadherence. 
 In summary, in a retrospective cohort of veterans 
with OSA newly started on CPAP therapy, we have 
demonstrated an association of adherence to lipid-
lowering medications and initial daily CPAP adher-
ence, independent of age, race, and clinical factors, 
but not of individual marital status. If cardiovascular 
medication adherence and CPAP adherence are 
linked in other observational study populations, 
then the magnitude of prior estimates of the impact 
of CPAP adherence on cardiovascular risk among 
patients with OSA might be infl ated by such unmea-
sured health-promoting behaviors. Our fi ndings 
argue for better assessment of potential confound-
ing factors in future observational studies of CPAP 
adherence and, where ethically feasible, for prospec-
tive, controlled evaluations of the potential benefi ts 
of CPAP. 
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